FDA Mandates Contraindication for Cetrain MRI Contrast Agents

FDA Mandates Contraindication for Cetrain MRI Contrast Agents Spangenberg Shibley & Liber LLP attorneys Peter J. Brodhead, William Hawal and Peter H. Weinberger are representing numerous Nephrogenic Systemic Fibrosis patients in their lawsuits against GE Healthcare and its drug Omniscan. Cleveland, OH (PRWEB) November 9, 2010 On September 9, 2010 the FDA announced its decision to require changes to the labeling of gadolinium-based contrast agents (GBCAs) for use with patients with impaired kidney function who undergo MRI procedures. These changes are intended to minimize the risk of
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations